These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33443332)

  • 1. [Ultra-rapid lispro (Lyumjev®)].
    Philips JC; Paquot N
    Rev Med Liege; 2021 Jan; 76(1):64-68. PubMed ID: 33443332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is the value of faster acting prandial insulin? Focus on ultra rapid lispro.
    Heise T; Piras de Oliveira C; Juneja R; Ribeiro A; Chigutsa F; Blevins T
    Diabetes Obes Metab; 2022 Sep; 24(9):1689-1701. PubMed ID: 35593434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultra-rapid lispro shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early phase study.
    Leohr J; Kazda C; Liu R; Reddy S; Dellva MA; Matzopoulos M; Loh MT; Hardy T; Klein O; Kapitza C
    Diabetes Obes Metab; 2022 Feb; 24(2):187-195. PubMed ID: 34605142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultra rapid lispro (Lyumjev®) shortens time to recovery from hyperglycaemia compared to Humalog® in individuals with type 1 diabetes on continuous subcutaneous insulin infusion.
    Leohr J; Dellva MA; LaBell E; Coutant DE; Arrubla J; Plum-Mörschel L; Zijlstra E; Fukuda T; Hardy T
    Diabetes Obes Metab; 2024 Jan; 26(1):215-223. PubMed ID: 37814517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study.
    Heise T; Linnebjerg H; Coutant D; LaBell E; Zijlstra E; Kapitza C; Bue-Valleskey J; Zhang Q; Dellva MA; Leohr J
    Diabetes Obes Metab; 2020 Oct; 22(10):1789-1798. PubMed ID: 32436641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultra rapid lispro (URLi) shows accelerated pharmacokinetics and greater reduction in postprandial glucose versus Humalog® in patients with type 1 diabetes mellitus in a randomized, double-blind meal test early-phase study.
    Kazda C; Leohr J; Liu R; Reddy S; Dellva MA; Loh MT; Hardy T; Plum-Mörschel L
    Diabetes Obes Metab; 2022 Feb; 24(2):196-203. PubMed ID: 34595812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ultra-Rapid Lispro Improves Postprandial Glucose Control and Time in Range in Type 1 Diabetes Compared to Lispro: PRONTO-T1D Continuous Glucose Monitoring Substudy.
    Malecki MT; Cao D; Liu R; Hardy T; Bode B; Bergenstal RM; Bue-Valleskey J
    Diabetes Technol Ther; 2020 Nov; 22(11):853-860. PubMed ID: 32453647
    [No Abstract]   [Full Text] [Related]  

  • 8. The continuing quest for better subcutaneously administered prandial insulins: a review of recent developments and potential clinical implications.
    Owens DR; Bolli GB
    Diabetes Obes Metab; 2020 May; 22(5):743-754. PubMed ID: 31930670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin lispro: a review of its pharmacological properties and therapeutic use in the management of diabetes mellitus.
    Wilde MI; McTavish D
    Drugs; 1997 Oct; 54(4):597-614. PubMed ID: 9339963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog
    Leohr J; Dellva MA; Coutant DE; LaBell E; Heise T; Andersen G; Zijlstra E; Hermanski L; Nosek L; Linnebjerg H
    Clin Pharmacokinet; 2020 Dec; 59(12):1601-1610. PubMed ID: 32468448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog
    Linnebjerg H; Zhang Q; LaBell E; Dellva MA; Coutant DE; Hövelmann U; Plum-Mörschel L; Herbrand T; Leohr J
    Clin Pharmacokinet; 2020 Dec; 59(12):1589-1599. PubMed ID: 32468447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures.
    Roach P; Woodworth JR
    Clin Pharmacokinet; 2002; 41(13):1043-57. PubMed ID: 12403642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin lispro: its role in the treatment of diabetes mellitus.
    Campbell RK; Campbell LK; White JR
    Ann Pharmacother; 1996 Nov; 30(11):1263-71. PubMed ID: 8913409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus.
    Chapman TM; Noble S; Goa KL
    Drugs; 2002; 62(13):1945-81. PubMed ID: 12215068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin lispro: a pharmacoeconomic review of its use in diabetes mellitus.
    Dunn CJ; Plosker GL
    Pharmacoeconomics; 2002; 20(14):989-1025. PubMed ID: 12403639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultra-rapid BioChaperone Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14-day crossover treatment study in people with type 1 diabetes.
    Andersen G; Meiffren G; Lamers D; DeVries JH; Ranson A; Seroussi C; Alluis B; Gaudier M; Soula O; Heise T
    Diabetes Obes Metab; 2018 Nov; 20(11):2627-2632. PubMed ID: 29923294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultra Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs Humalog
    Leohr J; Dellva MA; Carter K; LaBell E; Linnebjerg H
    Clin Pharmacokinet; 2021 Nov; 60(11):1423-1434. PubMed ID: 34041713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultra rapid lispro showed greater reduction in postprandial glucose versus Humalog in children, adolescents and adults with type 1 diabetes mellitus.
    Aronson R; Biester T; Leohr J; Pollom R; Linnebjerg H; LaBell ES; Zhang Q; Coutant DE; Danne T
    Diabetes Obes Metab; 2023 Jul; 25(7):1964-1972. PubMed ID: 36974352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reducing hypoglycaemia with insulin analogues.
    Heller S
    Int J Obes Relat Metab Disord; 2002 Sep; 26 Suppl 3():S31-6. PubMed ID: 12174321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing Time in Range with Postprandial Glucose-Focused Titration of Ultra Rapid Lispro (URLi) in People with Type 1 Diabetes.
    Bergenstal RM; Bode BW; Bhargava A; Wang Q; Knights AW; Chang AM
    Diabetes Ther; 2023 Nov; 14(11):1933-1945. PubMed ID: 37740871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.